Eli Lilly has added another candidate to a growing pipeline of therapies for amyotrophic lateral sclerosis (ALS), tapping UK ...

The phase 2 PIVOT-HD trial of Novartis-partnered PTC518 (votoplam) showed that the oral mRNA splicing modifier was able to ...

The 'Choose Europe for Science' scheme was revealed by President of the European Commission Ursula Von Der Leyen during a ...

Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

That is according to the chief executive of the American Association for the Advancement of Science (AAAS), Sudip Parikh, who ...

Meanwhile, there was more encouraging news for the UK's science base after it emerged that the country's research teams have ...

But international agreements are notoriously difficult to enforce, and pharma companies and patient advocates who were ...

President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained ...

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, ...

According to the WSJ, the universal vaccine project is being pioneered by two recently appointed senior scientists in the NIH ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...